Background
Patient response to medication therapy is highly variable, and adverse events in children are often unpredictable. Some patients may have significant adverse reactions to standard doses of a given drug and require a reduced dose, whereas others may require a substantially larger dose of the same drug to achieve a similar exposure and presumably an equivalent therapeutic response. Over the last 2 decades, a dramatic increase has occurred in our understanding of how drug response may be influenced by variations in a single gene (pharmacogenetics), gene networks, and/or the entire genome (pharmacogenomics). With the completion of the Human Genome (2003) and International HapMap (2007) Projects, the information and tools necessary to identify important gene-response associations are now widely available. Increased availability of genetic tests in clinical laboratories (including direct-toconsumer testing) and decreasing analytical costs are also facilitating the uptake of pharmacogenomic testing in patient care. The promise of precision medicine is therefore steadily working its way into clinical care. There is no doubt that pharmacogenomics now plays an important role in drug development, 1-4 regulation, and prescribing. For pharmacists, pharmacogenom-ics is also proving to be a powerful clinical tool that, when used to develop individualized treatment plans for children, may ultimately increase the likelihood of selecting the right drug at the right dose for the right patient, reducing the risk of adverse drug events and/ or treatment failure.
The widespread clinical implementation of pharmacogenomics has admittedly been slower than anticipated following completion of the Human Genome Project; however, advancing pharmacogenomics into clinical practice remains a national healthcare priority. At the forefront of this effort are federal organizations such as the National Institutes of Health, which created and provided funding for a collaborative research network dedicated to the discovery of clinically relevant gene/ drug response associations (the Pharmacogenomics Research Network [PGRN]). As a result of PGRN-sponsored research, the Pharmacogenomics Knowledge Base, a leading, publicly available database in the field of pharmacogenomics, has been created. The Clinical Pharmacogenetics Implementation Consortium, an extension of the PGRN, was formed in 2009 to address barriers to clinical implementation and to develop and update actionable drug-gene guidelines to guide medication and dose selection based on pharmacogenomic test results. The first of these guidelines, published in March 2011, provides dosing recommendations for the thiopurine drugs based on the thiopurine methyltransferase genotype. 5 Currently, Clinical Pharmacogenetics Implementation Consortium guidelines are available for 36 medications (cpicpgx.org/guidelines), albeit with limited pediatric-specific recommendations. 6
Potential Roles and Activities for Pediatric Pharmacists in Pharmacogenomics
The roles that pharmacists play in clinical pharmacogenomics are more defined since the publication of the original position statement in 2011; however, there are still great opportunities for our profession and practice specialty to advocate for, and to establish the role of, pediatric pharmacists in pharmacogenomics. In their role as part of the multidisciplinary team, pediatric pharmacists routinely make medication and dose recommendations based on several clinical factors, including a child's age, physiology, concomitant medications, and diagnosis. Understanding a patient's pharmacogenomic information, including the ontogeny of these drug-metabolizing enzymes, transporters, and receptors, increases the likelihood of selecting a medication that is safe and effective for the individual. The pediatric pharmacist may use this knowledge to proactively reduce the risk of untoward adverse drug events while also avoiding therapeutic failures. Based on their education and training, pediatric pharmacists with a working knowledge of pharmacogenomics are arguably the most appropriate members of the medical team to recommend pharmacogenomic testing and to provide an interpretation of results in the context of a child's pharmacotherapy. Pediatric clinical pharmacists also routinely serve on pharmacy and therapeutics committees and work closely with pharmacy information technology support. In these roles they are well positioned to recommend gene/drug pairs for implementation within an institution as well as to create clinical decision support tools that are tailor-made for prescribing physicians, physician assistants, and nurse practitioners. While children pose unique challenges for pharmacogenomic interpretation, as compared to adults, successful implementation programs already exist at hospitals such as St. Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, and Children's Minnesota.
Challenges and Opportunities in Pharmacogenomics Education and Training
The Accreditation Council for Pharmacy Education 2016 Standards include pharmacogenomics as a required element of the didactic Doctor of Pharmacy curriculum, and graduates of contemporary pharmacy programs are expected to be "practice-ready" with respect to integrating genetic information into patient-centered pharmaceutical care. 7 Although the number of colleges or schools including pharmacogenomics in their didactic curriculum continues to grow, pharmacogenomic instruction remains inadequate, especially in areas related to pediatric-specific topics. [8] [9] [10] Opportunities for experiential and/or practice-based training within Doctor of Pharmacy programs are also uncommon, with only a few programs offering elective Advanced Pharmacy Practice Experiences in precision medicine and/or pharmacogenomics. Consequently, many practicing pharmacists lack confidence and feel inadequately prepared to apply this information in practice. 11 Opportunities Some hospital systems have also developed continuing education for their pharmacists. The Children's Hospital of Wisconsin developed an online and live module course based on objectives from the National Coalition for Health Professional Education in Genetics guidelines. 13 The online module includes introductory concepts on genetics and pharmacogenomics, particularly related to antiepileptic medications, and is a required competency for all pharmacists to provide pharmacogenomic services at the hospital. 14 St. Jude Children's Research Hospital has also developed educational programs for their pharmacists to complete before providing pharmacogenomic consultation, serving as an example for other institutions to follow.
Recommendations
The Pediatric Pharmacy Advocacy Group (PPAG) endorses the involvement of pediatric pharmacists in pharmacogenomic testing and believes that pharmacists should be the healthcare professionals responsible for ordering, interpreting, and applying pharmacogenomic test results as they relate to pediatric pharmacotherapy. The PPAG also strongly encourages pharmacists to take responsibility for educating patients and their families about pharmacogenomic testing, especially in the community setting, where direct-to-consumer genetic test kits are readily available to patients and caregivers. The PPAG acknowledges a need for increased application-based education of both students and practicing pharmacists, which should incorporate clinical applications, such as interpretation of test results with consideration of infants and children. The PPAG believes that pharmacogenomics is an emerging discipline that will become increasingly important in pediatric pharmacotherapy. As genotype-based dosing recommendations are developed and updated, the need for pediatric pharmacists trained in this discipline will become essential. Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.
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